Stockscreener 앱 받기
4.23
3.20%
-0.14
전일 마감가:
$4.37
열려 있는:
$4.41
하루 거래량:
9.92M
Relative Volume:
0.66
시가총액:
$1.89B
수익:
$285.55M
순이익/손실:
$-353.86M
주가수익비율:
-4.4522
EPS:
-0.9501
순현금흐름:
$-305.02M
1주 성능:
-1.86%
1개월 성능:
+11.90%
6개월 성능:
+72.65%
1년 성능:
+119.17%
1일 변동 폭
$4.145
$4.45
1주일 범위
$4.07
$4.5399
52주 변동 폭
$1.70
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.23 | 1.89B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 업그레이드 | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Why Is IOVA Stock Falling Today? - Stocktwits
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool
Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
symbol__ Stock Quote Price and Forecast - CNN
IOVAIovance Biotherapeutics Inc Options - Finviz
Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance - TradingView
Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028 - Stock Titan
IOVA Stock Price, Quote & Chart - ChartMill
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen - ChartMill
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join - The National Law Review
Why Iovance Biotherapeutics (IOVA) Is Up 7.7% After Australian Conditional OK For Amtagvi Cell Therapy - Sahm
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Ge - The National Law Review
Investor Alert: Deadline Approaching to Join Iovance Biotherapeut - The National Law Review
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics - The National Law Review
IOVA Stockholders Have Opportunity to Lead Iovance Biotherapeutic - The National Law Review
Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView
Price to sales forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Price to sales forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to book forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Price to earnings forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Enterprise value to EBITDA forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to earnings forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to book forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA) - TradingView
Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma - Sahm
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
5 Resilient Stocks During Market Bloodbath - Insider Monkey
Iovance (IOVA) Surges 9.4% on Regulatory Nod - Insider Monkey
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale - TechStock²
IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands - StocksToTrade
Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings - Sahm
Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules. - Pluang
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):